Introduction

The American Diabetes Association (ADA) has been actively involved in the development and dissemination of diabetes care standards, guidelines, and related documents for many years. These statements are published in one or more of the Association's professional journals. This Supplement contains ADA's “Standards of Medical Care in Diabetes,” our major position statement, which contains all or key recommendations. In addition, contained herein are selected position statements on certain topics not adequately covered in the “Standards.” We hope that this is a convenient and important resource for all health care professionals who care for people with diabetes.

ADA Clinical Practice Recommendations consist of position statements that represent official ADA opinion as denoted by formal review and approval by the Professional Practice Committee. ADA Statements, consensus statements, and technical reviews are not official ADA recommendations; however, they are produced under the auspices of the Association by invited experts. These publications are reviewed by the Professional Practice Committee for general content and used as source documents for the updating of the “Standards.”

ADA has adopted the following definitions for its clinically related reports.

Position statement: An official point of view or belief of the ADA. Position statements are issued on scientific or medical issues related to diabetes. They are published in ADA journals and other scientific/medical publications as appropriate. Position statements must be reviewed and approved by the Professional Practice Committee and, subsequently, by the Executive Committee of the Board of Directors. ADA position statements are typically based on a technical review or other published review and are peer reviewed on an annual basis. A list of position statements is included on p. S69 of this supplement.

ADA Statement: A focused review on a clinical topic with recommendations. It is authored, and the recommendations are those of the authors based on the evidence presented. ADA Statements are reviewed externally and also by the Professional Practice Committee for overall content. As noted above, the recommendations made are considered by the Professional Practice Committee as part of the review and updating of the “Standards of Medical Care in Diabetes.” A list of ADA Statements is included on p. S69 of this supplement.

Technical review: A balanced review and analysis of the literature on a scientific or medical topic related to diabetes. The technical review provides a scientific rationale for a position statement and undergoes peer review before submission to the Professional Practice Committee for approval. In some cases, in place of a technical review, original research publications, conference proceedings, or other comprehensive review articles are used as a basis for a position statement. A list of technical reviews is included on page S64 of this supplement.

Consensus statement: A comprehensive examination by a panel of experts (i.e., consensus panel) of a scientific or medical issue related to diabetes. A consensus statement is developed immediately following a consensus conference at which presentations are made on the issue under review. The statement represents the panel’s collective analysis, evaluation, and opinion based in part on the conference proceedings. The need for a consensus conference arises when clinicians or scientists desire guidance on a subject for which there is a relative deficiency of “evidence” that might otherwise allow a more definite statement to be made. Once writ-

<table>
<thead>
<tr>
<th>Level of evidence</th>
<th>Description</th>
</tr>
</thead>
</table>
| A                 | Clear evidence from well-conducted, generalizable, randomized controlled trials that are adequately powered, including:  
• Evidence from a well-conducted multicenter trial  
• Evidence from a meta-analysis that incorporated quality ratings in the analysis  
• Compelling nonexperimental evidence, i.e., “all or none” rule developed by the Center for Evidence Based Medicine at Oxford*  
Supportive evidence from well-conducted randomized controlled trials that are adequately powered, including:  
• Evidence from a well-conducted trial at one or more institutions  
• Evidence from a meta-analysis that incorporated quality ratings in the analysis |
| B                 | Supportive evidence from well-conducted cohort studies, including:  
• Evidence from a well-conducted prospective cohort study or registry  
• Evidence from a well-conducted meta-analysis of cohort studies  
Supportive evidence from a well-conducted case-control study |
| C                 | Supportive evidence from poorly controlled or uncontrolled studies, including:  
• Evidence from randomized clinical trials with one or more major or three or more minor methodological flaws that could invalidate the results  
• Evidence from observational studies with high potential for bias (such as case series with comparison with historical controls)  
• Evidence from case series or case reports  
Conflicting evidence with the weight of evidence supporting the recommendation |
| D                 | Expert consensus or clinical experience |

*Either all patients died before therapy and at least some survived with therapy or some patients died without therapy and none died with therapy. Example: use of insulin in the treatment of diabetic ketoacidosis.
Introduction

ten by the panel, a consensus statement is not subject to subsequent review or approval and does not represent official Association opinion. A list of recent consensus statements is included on p. S64 of this supplement.

The Association’s Professional Practice Committee is responsible for reviewing official position statements. Appointment to the Professional Practice Committee is based on excellence in clinical practice and research. The committee comprises physicians, diabetes educators, and registered dietitians who have expertise in a range of areas, including adult and pediatric endocrinology, epidemiology and public health, lipid research, hypertension, and preconception and pregnancy care. The committee regularly reviews each previously approved statement and makes necessary revisions. Both new and revised position statements are also reviewed by outside experts, after which they are approved by the Executive Committee.

Grading of scientific evidence: Since the ADA first began publishing practice guidelines, considerable evolution has occurred in the evaluation of scientific evidence and in the development of evidence-based guidelines. Accordingly, we have developed a classification system to grade the quality of scientific evidence supporting ADA recommendations. The system outlined in Table 1 will be used for all new and revised ADA position statements.

Recommendations have been assigned ratings of A, B, or C, depending on the quality of evidence (Table 1). Expert opinion (E) is a separate category for recommendations in which there is as yet no evidence from clinical trials, in which clinical trials may be impractical, or in which there is conflicting evidence. Recommendations with an “A” rating are based on large well-designed clinical trials or well-done meta-analyses. Generally, these recommendations have the best chance of improving outcomes when applied to the population to which they are appropriate. Recommendations with lower levels of evidence may be equally important but are not as well supported. This supplement contains seven statements that have used this system. The level of evidence supporting a given recommendation is noted either as a heading for a group of recommendations or after a given recommendation in parentheses.

Of course, evidence is only one component of clinical decision-making. Clinicians care for patients, not populations; guidelines must always be interpreted with the needs of the individual patient in mind. Individual circumstances, such as comorbid and coexisting diseases, age, education, disability, and, above all, patients’ values and preferences, must also be considered and may lead to different treatment targets and strategies. Also, conventional evidence hierarchies, such as the one adapted by the ADA, may miss some nuances that are important in diabetes care. For example, while there is excellent evidence from clinical trials supporting the importance of achieving glycemic control, the optimal way to achieve this result is less clear. It is difficult to assess each component of such a complex intervention.

The ADA will continue to improve and update the Clinical Practice Recommendations to ensure that clinicians, health plans, and policy makers can continue to rely on them as the most authoritative and current guidelines for diabetes care.

We hope you find this compilation useful. Our Clinical Practice Recommendations are also available on the Association’s website at www.diabetes.org/diabetescare.